期刊文献+

氯雷他定联合玉屏风散加味治疗慢性荨麻疹临床疗效观察 被引量:12

Observation of Therapeutic Effect of Loratadine Combined Modified Yupingfengsan on Chronic Urticaria
下载PDF
导出
摘要 目的观察氯雷他定联合玉屏风散治疗慢性荨麻疹的疗效。方法将荨麻疹患者130例随机分为治疗组70例和对照组60例。治疗组口服玉屏风散,1剂/日,氯雷他定10mg,1次/日;对照组口服氯雷他定10mg,1次/日;两组均分别于用药后第7、14、28天观察疗效和不良反应。结果治疗组与对照组的有效率分别为91.43%和66.67%,两组比较差异有统计学意义(P<0.05);两组均未见明显不良反应。结论玉屏风散联合氯雷他定治疗慢性荨麻疹疗效显著。 Objective To observe the therapeutic effect of loratadine combined modified Yupingfengsan on chronic urticaria. Methods 130 patients with chronic urticaria were divieded into two groups randamly, 70 patients in the treatment group were given modified Yupingfengsan and loratadine, 60 patients in the control group were only given loratadine. Observe the efficacy and adverse reactions after 7 days, 14 days,and 28 days respectively. Results The effective rates of treatment group and control group were 91.43% vs 66. 67% ,and there was significant difference between the two groups(P〈0.05). In addition,mild adverse reactions were found in two groups. Conclusion Loratadine combined modified Yupingfengsan were effective for the treatment of chronic urticaria.
机构地区 永丰县人民医院
出处 《中西医结合研究》 2011年第6期288-290,共3页 Research of Integrated Traditional Chinese and Western Medicine
关键词 玉屏风散 氯雷他定 慢性荨麻疹 Yupingfengsan loratadine chronic urticaria
  • 相关文献

参考文献6

二级参考文献24

  • 1[1]Simons FER,Simons KJ. Clinical pharmacology of new histamine H1 antagonists[J]. Clin Pharmacokinet, 1999, 36: 329. 被引量:1
  • 2[2]Yumibe N, Huie K, Chen KJ, et al. Identification of human liver cytochrome P450 enzymes that metabolizethe nonsedating antihistamine loratadine. Formation ofdescarboethoxyloratadine by CYP3A4 and CYP2D6[J].Biochem Pharmacol, 1996, 51:165. 被引量:1
  • 3[3]Handley DA, Mccullough JR, Fang Y, et al. Descarboet-hoxyloratadine, a metabolite of loratadine, is a superiorantihistamine[J]. Ann Allergy Asthma Immunol, 1997,78(1):164. 被引量:1
  • 4[4]Anthes JC, Richard C, West RE, et al. Functional char-acterization of desloratadine and other antihistaminesin a Chinese hamster ovary(CHO)cell line that expressthe cloned human histamine H1 receptor and in humanbronchial smooth muscle cells(HBSNC)[J] .J AllergyClin Immunol, 2000, 105(1, Part 2): 1 125. 被引量:1
  • 5[5]Agrawal DK.Antiinflammator properties of deslorata-dine (DCL) :Effects on eosinophil chemotaxis, adhesionand release of superoxide anions[J].J Allergy Clin Im-munol, 2000, 105(1, Part 2): 49. 被引量:1
  • 6[6]Berthon B, Taudou G, Combettes L, et al. In vitro in-hibition, by loratadine and descarboethoxyloratadine, ofhistamine release from human basophils, and of histam-ine release and intracellular calcium fluxes in rat baso-philic leukemia cells (RBL-2H3)[J] .Biochem Phar-macol, 1994, 47: 789. 被引量:1
  • 7[7]Vignola AM, Crampette L, Mondain M, et al. Inhibito-ry activity of loratadine and descarboethoxyloratadineon expression of ICAM-1 and HLA-DR by nasal ep-ithelial cells[J]. Biochem Pharmacol, 1995, 52:200. 被引量:1
  • 8[8]Kreumer W, Hey JA, Anthes J, et al. Preclinical effica-cy and antiallergic profile of desloratadine, a selectiveand nonsedating histamine H1 receptor antagonist[J].J Allergy Clin Immunol, 2000, 105(1, Part 2): 1 118. 被引量:1
  • 9[9]Padhi D,Banfield C,Gupta S,et al. Multiple-dose pha-rmacokinetics, safety, and tolerance of desloratadine inhealthy volunteers[J] .J Allergy Ciin lmmunol, 2000,105(1, Part 2): 1 124. 被引量:1
  • 10[10]Herron JM,Padhi D,Affrime MB, et al. Dose-proport-ionality, linearity, and pharmacokinetics of desloratadi-ne in healthy adults[J]. J Allergy Clin Immunol, 2000,105(1,Part 2):1 126. 被引量:1

共引文献135

同被引文献99

引证文献12

二级引证文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部